NasdaqGS:OSUR

Stock Analysis Report

Executive Summary

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally.

Rewards

Loading interface...

Risk Analysis

Loading interface...

Snowflake Analysis

Flawless balance sheet with proven track record.


Similar Companies

Share Price & News

How has OraSure Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Information is not available.


Market Performance


7 Day Return

2.8%

OSUR

-0.02%

US Medical Equipment

1.3%

US Market


1 Year Return

-32.9%

OSUR

22.3%

US Medical Equipment

19.4%

US Market

Information is not available.

Information is not available.


Shareholder returns

OSURIndustryMarket
7 Day2.8%-0.02%1.3%
30 Day-3.0%3.9%2.6%
90 Day4.9%3.9%5.0%
1 Year-32.9%-32.9%23.3%22.3%22.0%19.4%
3 Year-15.0%-15.0%90.4%84.7%46.8%37.3%
5 Year-18.8%-18.8%117.4%93.7%66.3%48.0%

Price Volatility Vs. Market

How volatile is OraSure Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is OraSure Technologies undervalued compared to its fair value and its price relative to the market?

19.99x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Information is not available.

Information is not available.


Price To Earnings Ratio

Information is not available.

Information is not available.


Price to Earnings Growth Ratio

Information is not available.


Price to Book Ratio

Information is not available.


Next Steps

Future Growth

How is OraSure Technologies forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-18.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Information is not available.

Information is not available.

Information is not available.

Information is not available.

Information is not available.


Earnings per Share Growth Forecasts


Future Return on Equity

Information is not available.


Next Steps

Past Performance

How has OraSure Technologies performed over the past 5 years?

31.2%

Historical annual earnings growth


Earnings and Revenue History

Information is not available.

Information is not available.


Past Earnings Growth Analysis

Information is not available.

Information is not available.

Information is not available.


Return on Equity

Information is not available.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is OraSure Technologies's financial position?


Financial Position Analysis

Information is not available.

Information is not available.


Debt to Equity History and Analysis

Information is not available.

Information is not available.

Information is not available.

Information is not available.


Balance Sheet

Information is not available.

Information is not available.


Next Steps

Dividend

What is OraSure Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry

Information is not available.

Information is not available.


Stability and Growth of Payments

Information is not available.

Information is not available.


Current Payout to Shareholders

Information is not available.


Future Payout to Shareholders

Information is not available.


Next Steps

Management

What is the CEO of OraSure Technologies's salary, the management and board of directors tenure and is there insider trading?

2.3yrs

Average management tenure


CEO

Steve Tang (58yo)

1.7yrs

Tenure

US$2,099,594

Compensation

Dr. Stephen S. Tang, also known as Steve, Ph.D. has been President and Chief Executive Officer at OraSure Technologies, Incorporation since April 01, 2018. Dr. Tang has been Chief Executive Officer and Pre ...


CEO Compensation Analysis

Information is not available.

Information is not available.


Management Age and Tenure

2.3yrs

Average Tenure

58yo

Average Age

Information is not available.


Board Age and Tenure

3.1yrs

Average Tenure

59yo

Average Age

Information is not available.


Insider Trading

Information is not available.


Recent Insider Transactions

BuyUS$8,56014 May 19
Stephen Tang
EntityIndividual
Role
Chief Executive Officer
President
Shares1,000
Max PriceUS$8.56
BuyUS$85,48714 May 19
Jack Jerrett
EntityIndividual
Role
Chief Legal Officer
Senior VP
Shares10,000
Max PriceUS$8.55
BuyUS$90,31414 May 19
Roberto Cuca
EntityIndividual
Role
Chief Financial Officer
CFO & Principal Accounting Officer
Shares10,000
Max PriceUS$9.04

Ownership Breakdown

Information is not available.


Management Team

  • Steve Tang (58yo)

    President

    • Tenure: 1.7yrs
    • Compensation: US$2.10m
  • Jack Jerrett (60yo)

    Senior VP

    • Tenure: 19.1yrs
    • Compensation: US$973.46k
  • Roberto Cuca (51yo)

    CFO & Principal Accounting Officer

    • Tenure: 1.5yrs
    • Compensation: US$1.05m
  • Brian Smith (60yo)

    Vice Chairman & EVP of Innovation - DNA Genotek

    • Tenure: 2.3yrs
    • Compensation: US$978.65k
  • David Rappaport

    Senior Vice President of Business Development

    • Tenure: 1.7yrs
  • Nancy McLane

    Senior Vice President of Operations

    • Tenure: 0yrs
  • Jeanne Mell

    Vice President of Corporate Communications

    • Tenure: 1.3yrs
  • Tony Zezzo (65yo)

    Executive VP & Business Unit Leader of Infectious Disease

    • Tenure: 2.9yrs
    • Compensation: US$1.06m
  • Kathy Weber (52yo)

    Executive VP & Business Unit Leader of Molecular Solutions

    • Tenure: 7.1yrs
  • Mike Reed (50yo)

    Senior VP of R&D and Chief Science Officer

    • Tenure: 3.7yrs
    • Compensation: US$778.96k

Board Members

  • Chuck Patrick (64yo)

    Independent Director

    • Tenure: 13.9yrs
    • Compensation: US$168.99k
  • Eamonn Hobbs (60yo)

    Independent Director

    • Tenure: 3.8yrs
    • Compensation: US$157.24k
  • Steve Tang (58yo)

    President

    • Tenure: 1.7yrs
    • Compensation: US$2.10m
  • Ronny Lancaster (67yo)

    Independent Director

    • Tenure: 16.6yrs
    • Compensation: US$169.74k
  • Mike Celano (60yo)

    Independent Chairman of the Board

    • Tenure: 1.7yrs
    • Compensation: US$506.36k
  • James Datin (56yo)

    Director

    • Tenure: 0.3yrs
  • Mara Aspinall (57yo)

    Independent Director

    • Tenure: 2.5yrs
    • Compensation: US$157.24k
  • Aradhana Sarin (44yo)

    Independent Director

    • Tenure: 1.8yrs
    • Compensation: US$562.31k

Company Information

OraSure Technologies, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: OraSure Technologies, Inc.
  • Ticker: OSUR
  • Exchange: NasdaqGS
  • Founded: 2000
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$491.342m
  • Shares outstanding: 61.73m
  • Website: https://www.orasure.com

Number of Employees


Location

  • OraSure Technologies, Inc.
  • 220 East First Street
  • Bethlehem
  • Pennsylvania
  • 18015
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OSURNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 1986
EP3DB (Deutsche Boerse AG)YesCommon StockDEEURNov 1986

Biography

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and inter ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/12 23:43
End of Day Share Price2019/12/12 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.